GW Pharmaceuticals PLC (GWPH.OQ)
19 Sep 2018
Latest Key Developments (Source: Significant Developments)
Aug 7 (Reuters) - GW Pharmaceuticals PLC
June 25 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - APPROVED EPIDIOLEX (CANNABIDIOL) ORAL SOLUTION FOR TREATMENT OF SEIZURES ASSOCIATED WITH 2 SEVERE FORMS OF EPILEPSY IN PATIENTS 2 YRS & OLDER.U.S. FDA - FDA GRANTED APPROVAL OF EPIDIOLEX TO GW RESEARCH LTD.U.S. FDA - EPIDIOLEX APPROVED FOR TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME & DRAVET SYNDROME IN PATIENTS 2 YRS & OLDER. Full Article
Dec 13 (Reuters) - GW Pharmaceuticals Plc
Dec 5 (Reuters) - Gw Pharmaceuticals Plc
LONDON British scientists have unraveled how a non-intoxicating component of cannabis acts in key brain areas to reduce abnormal activity in patients at risk of psychosis, suggesting the ingredient could become a novel anti-psychotic medicine.